ITROM Pharmaceutical Signs an Exclusive License & Commercialization Agreement with Mithra for 20 years

 ITROM Pharmaceutical Signs an Exclusive License & Commercialization Agreement with Mithra for 20 years

ITROM Pharmaceutical Signs an Exclusive License & Commercialization Agreement with Mithra for 20 years

Shots:

  • ITROM to get exclusive commercialization rights for Mithra’s Myring in MENA territories (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman, Lebanon, and Jordan) with a total deal value of $6.79M. Mithra strengthen its portfolio and manufacture it at CDMO facility in Belgium
  • The focus of the agreement is to develop and commercialize techniques for women in fields of fertility, contraception, Hormonal Therapy (HT) & personal care and generate $15.8M in combination with their deal, in Dec 2018 to commercialize Mithra’s Tibelia and Daphne Continu
  • Myring (etonogestrel, 11.7mg /ethinyl estradiol,2.7mg) is a generic of NuvaRing a contraceptive vaginal ring, made of ethylene vinyl acetate copolymers for the prevention of pregnancy

Click here to read full press release/ article | Ref: Mithra | Image: Mithra

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post